Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

142
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
142
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

137
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
137
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

115
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
115

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acuity, Diagnosis, and Community Factors in Virtual and In-Person Treatment: Qualitative Study.

JMIR human factors·2026
Same author

Understanding Therapeutic Experience: A Qualitative Evaluation of Virtual and In-Person Treatment.

Cureus·2025
Same author

Using Design Thinking to Understand the Reason for Headache Referrals and Reduce Referral Rates.

Neurology. Clinical practice·2024
Same author

The Impact of SARS-CoV-2 (COVID-19) on the Acuity of Mental Health-Related Diagnosis at Admission for Young Adults in New York City and Washington, DC: Observational Study.

JMIR formative research·2022
Same author

Improvement of stiff-person syndrome symptoms in pregnancy: Case series and literature review.

Neurology(R) neuroimmunology & neuroinflammation·2020
Same author

Diagnosis influences response of cerebral near infrared spectroscopy to intracranial hypertension in children.

Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·2009

Related Experiment Video

Updated: Jun 5, 2025

Modeling Colitis-Associated Cancer with Azoxymethane AOM and Dextran Sulfate Sodium DSS
12:37

Modeling Colitis-Associated Cancer with Azoxymethane AOM and Dextran Sulfate Sodium DSS

Published on: September 11, 2012

46.8K

Ofatumumab-associated colitis: A case report.

Ashish D Patel1, Alexa Connors1, Megan E Esch1

  • 1Department of Neurology, Geisinger Health System, Danville, PA, USA.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|December 7, 2024
PubMed
Summary
This summary is machine-generated.

A first case of colitis linked to ofatumumab, an anti-CD20 therapy, in multiple sclerosis (MS) patients is reported. This suggests a potential class effect, urging vigilance for gastrointestinal symptoms in MS patients on anti-CD20 treatments.

Keywords:
Ofatumumabadverse effectanti-CD20 therapycolitisinflammatory bowel diseasemultiple sclerosis

More Related Videos

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.1K
Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
06:57

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Published on: September 18, 2016

9.0K

Related Experiment Videos

Last Updated: Jun 5, 2025

Modeling Colitis-Associated Cancer with Azoxymethane AOM and Dextran Sulfate Sodium DSS
12:37

Modeling Colitis-Associated Cancer with Azoxymethane AOM and Dextran Sulfate Sodium DSS

Published on: September 11, 2012

46.8K
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.1K
Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
06:57

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Published on: September 18, 2016

9.0K

Area of Science:

  • Neuroimmunology
  • Gastroenterology
  • Pharmacology

Background:

  • Colitis is a known side effect of some anti-CD20 therapies used in multiple sclerosis (MS).
  • Ofatumumab, a B-cell depleting therapy, has not been previously associated with colitis in MS patients.

Purpose of the Study:

  • To document the initial instance of colitis associated with ofatumumab treatment in an MS patient.
  • To explore the broader implications of this adverse event within the context of anti-CD20 therapies for MS.

Main Methods:

  • A case report methodology was employed.
  • Detailed clinical information from a single patient was analyzed.

Main Results:

  • A 56-year-old female with relapsing-remitting multiple sclerosis (RRMS) experienced severe colitis.
  • Symptoms emerged three months after starting ofatumumab, necessitating hospitalization and cessation of the drug.

Conclusions:

  • This case highlights a potential class-wide effect of anti-CD20 therapies, including ofatumumab, regarding colitis in MS.
  • Healthcare providers should actively monitor MS patients undergoing anti-CD20 therapy for any gastrointestinal adverse events.